BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16568241)

  • 1. The clinical potential of sphingolipid-based therapeutics.
    Fox TE; Finnegan CM; Blumenthal R; Kester M
    Cell Mol Life Sci; 2006 May; 63(9):1017-23. PubMed ID: 16568241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Click reactions with functional sphingolipids.
    Fink J; Seibel J
    Biol Chem; 2018 Sep; 399(10):1157-1168. PubMed ID: 29908120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unfolding role of ceramide in coordinating retinoid-based cancer therapy.
    Ghandour B; Dbaibo G; Darwiche N
    Biochem J; 2021 Oct; 478(19):3621-3642. PubMed ID: 34648006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
    Gatt S; Dagan A
    Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic targets for atherosclerosis in sphingolipid metabolism.
    Yu Z; Peng Q; Huang Y
    Clin Sci (Lond); 2019 Mar; 133(6):763-776. PubMed ID: 30890654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
    Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
    Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic applications of bioactive sphingolipids in hematological malignancies.
    Ekiz HA; Baran Y
    Int J Cancer; 2010 Oct; 127(7):1497-506. PubMed ID: 20503271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceramide synthases at the centre of sphingolipid metabolism and biology.
    Mullen TD; Hannun YA; Obeid LM
    Biochem J; 2012 Feb; 441(3):789-802. PubMed ID: 22248339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceramide Metabolism and Parkinson's Disease-Therapeutic Targets.
    Custodia A; Aramburu-Núñez M; Correa-Paz C; Posado-Fernández A; Gómez-Larrauri A; Castillo J; Gómez-Muñoz A; Sobrino T; Ouro A
    Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34202192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular facets of sphingolipids: mediators of diseases.
    Ozbayraktar FB; Ulgen KO
    Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids as therapeutics.
    Kester M; Kolesnick R
    Pharmacol Res; 2003 May; 47(5):365-71. PubMed ID: 12676510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
    Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
    Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Ceramide Synthases in Mice and Their Roles in Regulating Acyl-Chain Sphingolipids: A Framework for Baseline Levels and Future Implications in Aging and Disease.
    Richardson WJ; Humphrey SB; Sears SM; Hoffman NA; Orwick AJ; Doll MA; Doll CL; Xia C; Hernandez-Corbacho M; Snider JM; Obeid LM; Hannun YA; Snider AJ; Siskind LJ
    Mol Pharmacol; 2024 Feb; 105(3):131-143. PubMed ID: 38164625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.
    Canals D; Perry DM; Jenkins RW; Hannun YA
    Br J Pharmacol; 2011 Jun; 163(4):694-712. PubMed ID: 21615386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipid metabolites in inflammatory disease.
    Maceyka M; Spiegel S
    Nature; 2014 Jun; 510(7503):58-67. PubMed ID: 24899305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipids in apoptosis.
    Tirodkar TS; Voelkel-Johnson C
    Exp Oncol; 2012 Oct; 34(3):231-42. PubMed ID: 23070008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.
    Barth BM; Wang W; Toran PT; Fox TE; Annageldiyev C; Ondrasik RM; Keasey NR; Brown TJ; Devine VG; Sullivan EC; Cote AL; Papakotsi V; Tan SF; Shanmugavelandy SS; Deering TG; Needle DB; Stern ST; Zhu J; Liao J; Viny AD; Feith DJ; Levine RL; Wang HG; Loughran TP; Sharma A; Kester M; Claxton DF
    Blood Adv; 2019 Sep; 3(17):2598-2603. PubMed ID: 31488436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.
    Mina JGM; Denny PW
    Parasitology; 2018 Feb; 145(2):134-147. PubMed ID: 28637533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family.
    Kováčik A; Roh J; Vávrová K
    Chembiochem; 2014 Jul; 15(11):1555-62. PubMed ID: 24990520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Development in the Field of Sphinogolipid Metabolism.
    Qu Z; Zhou L
    Adv Exp Med Biol; 2022; 1372():169-188. PubMed ID: 35503181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.